RAPT Therapeutics Proposed Sale to GSK Under Investigation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Should l Buy RAPT?
Source: Businesswire
- Investigation Launched: Former Louisiana Attorney General Charles C. Foti and Kahn Swick & Foti law firm are investigating the proposed sale of RAPT Therapeutics to GSK, aiming to assess the adequacy of the transaction process and its terms.
- Transaction Terms Overview: Under the proposed terms, RAPT shareholders will receive $58.00 in cash per share, raising questions about whether this price adequately reflects the company's value, necessitating further scrutiny.
- Legal Rights Consultation: KSF encourages shareholders who believe the transaction undervalues the company to reach out for discussions regarding their legal rights, indicating potential disputes surrounding the deal.
- Urgency Reminder: As the transaction is structured as a tender offer, KSF emphasizes the importance of prompt action by shareholders to ensure their rights are protected.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RAPT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RAPT
Wall Street analysts forecast RAPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPT is 67.78 USD with a low forecast of 56.00 USD and a high forecast of 95.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 57.780
Low
56.00
Averages
67.78
High
95.00
Current: 57.780
Low
56.00
Averages
67.78
High
95.00
About RAPT
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapies for patients living with inflammatory and immunological diseases. Its lead drug candidate, RPT904, is a half-life extended monoclonal antibody (mAb) designed to bind free human immunoglobin E (IgE), which is being developing for the treatment of food allergy, chronic spontaneous urticaria (CSU) and potentially other inflammatory diseases. The Company’s oncology drug candidate, tivumecirnon, is an oral small-molecule C-C motif chemokine receptor 4 (CCR4) antagonist designed to selectively inhibit the migration of immunosuppressive regulatory T cells (Treg) into tumors.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
RAPT Therapeutics Proposed Sale to GSK Under Investigation
- Investigation Launched: Former Louisiana Attorney General Charles C. Foti and Kahn Swick & Foti law firm are investigating the proposed sale of RAPT Therapeutics to GSK, aiming to assess the adequacy of the transaction process and its terms.
- Transaction Terms Overview: Under the proposed terms, RAPT shareholders will receive $58.00 in cash per share, raising questions about whether this price adequately reflects the company's value, necessitating further scrutiny.
- Legal Rights Consultation: KSF encourages shareholders who believe the transaction undervalues the company to reach out for discussions regarding their legal rights, indicating potential disputes surrounding the deal.
- Urgency Reminder: As the transaction is structured as a tender offer, KSF emphasizes the importance of prompt action by shareholders to ensure their rights are protected.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Initiated: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc. (NASDAQ: RAPT) regarding its sale to GSK plc for $58.00 per share, potentially violating fiduciary duties to shareholders and impacting shareholder rights.
- Shareholder Rights Protection: The transaction between Penumbra, Inc. (NYSE: PEN) and Boston Scientific Corporation involves $374.00 in cash or 3.8721 shares of Boston Scientific common stock per share, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
- Cash and Stock Transaction: Calavo Growers, Inc. (NASDAQ: CVGW) is selling to Mission Produce, Inc. for $14.85 in cash and 0.9790 shares of Mission stock per share, prompting Halper Sadeh LLC to assess the potential impact of this transaction on shareholders.
- Management Transaction Review: FONAR Corporation (NASDAQ: FONR) is involved in a transaction with its CEO and certain executives for $19.00 per share for Class B common stock and $6.34 per share for Class C common stock, with Halper Sadeh LLC possibly advocating for enhanced shareholder rights.
See More
Investigation Alerts for Multiple Company Mergers
- RAPT Acquisition Investigation: RAPT Therapeutics is set to be acquired by GlaxoSmithKline for $58 per share, totaling an estimated equity value of $2.2 billion, with investigations focusing on whether the board failed to conduct a fair process, potentially impacting shareholder rights.
- Calavo Merger Details: Calavo Growers will be acquired by Mission Produce, with shareholders receiving $27 per share, including $14.85 in cash and 0.9790 shares of Mission, valuing the transaction at approximately $430 million, while investigations examine if the board breached fiduciary duties to shareholders.
- Penumbra Acquisition Status: Penumbra will be acquired by Boston Scientific in a deal valuing the company at $374 per share, reflecting an enterprise value of about $14.5 billion, with investigations looking into whether the board ensured a fair process, potentially affecting shareholder interests.
- FONAR Merger Investigation: FONAR Corporation is to be acquired by FONAR, LLC for $19 per share in an all-cash transaction, with investigations questioning whether the board failed to conduct a fair process, which could impact shareholder rights.
See More
Halper Sadeh LLC Investigates Multiple Companies for Potential Violations
- Investigation Focus: Halper Sadeh LLC is investigating Janus Henderson Group plc, Amicus Therapeutics, Inc., and RAPT Therapeutics, Inc. for potential violations of federal securities laws related to their sales to Trian Fund Management, BioMarin Pharmaceutical, and GSK plc.
- Transaction Details: The cash sale price for Janus Henderson is $49.00 per share, Amicus is $14.50 per share, and RAPT is $58.00 per share, which may not adequately reflect the companies' true values, potentially harming shareholder interests.
- Shareholder Rights Protection: Halper Sadeh LLC may seek to secure increased consideration for shareholders, additional disclosures, and other relief measures to ensure the protection of shareholders' legal rights.
- Legal Service Commitment: The firm operates on a contingency fee basis, meaning shareholders are not responsible for out-of-pocket legal fees, and they encourage affected shareholders to consult for free regarding their legal rights and options.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Nathan’s Famous, Inc. (NASDAQ: NATH) for potential violations related to its sale to Smithfield Foods, Inc. for $102.00 per share in cash, aiming to protect shareholder rights and seek increased compensation.
- Transaction Details: Penumbra, Inc. (NYSE: PEN) is being sold for $374.00 in cash or 3.8721 shares of Boston Scientific common stock, with Halper Sadeh LLC potentially advocating for more information and compensation to ensure transaction transparency for shareholders.
- Legal Rights: RAPT Therapeutics, Inc. (NASDAQ: RAPT) is selling to GSK plc for $58.00 per share, and Halper Sadeh LLC encourages shareholders to reach out to understand their legal rights and options, ensuring their interests are safeguarded in the transaction.
- Shareholder Support: Lisata Therapeutics, Inc. (NASDAQ: LSTA) is being sold for $4.00 per share in cash plus two non-tradeable rights, with Halper Sadeh LLC offering contingent fee legal services to help shareholders secure their rightful interests in the potential transaction.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde & Associates is investigating the acquisition of Penumbra, Inc. by Boston Scientific Corporation, where shareholders are expected to receive either $374 in cash or 3.8721 shares of Boston Scientific, highlighting a commitment to shareholder rights.
- RAPT Transaction Details: In the sale of RAPT Therapeutics, Inc. to GSK plc, shareholders are anticipated to receive $58 in cash per share, reflecting positive market expectations regarding the transaction's value.
- Nathan's Famous Acquisition: Nathan’s Famous, Inc. is set to receive $102 in cash per share from Smithfield Foods, indicating a direct financial benefit to shareholders from this acquisition.
- Lisata Transaction Terms: Lisata Therapeutics, Inc. shareholders will receive $4 in cash per share along with potential contingent value rights in the sale to Smithfield Foods, suggesting future revenue opportunities for investors.
See More
RAPT Therapeutics Proposed Sale to GSK Under Investigation
- Investigation Launched: Former Louisiana Attorney General Charles C. Foti and Kahn Swick & Foti law firm are investigating the proposed sale of RAPT Therapeutics to GSK, aiming to assess the adequacy of the transaction process and its terms.
- Transaction Terms Overview: Under the proposed terms, RAPT shareholders will receive $58.00 in cash per share, raising questions about whether this price adequately reflects the company's value, necessitating further scrutiny.
- Legal Rights Consultation: KSF encourages shareholders who believe the transaction undervalues the company to reach out for discussions regarding their legal rights, indicating potential disputes surrounding the deal.
- Urgency Reminder: As the transaction is structured as a tender offer, KSF emphasizes the importance of prompt action by shareholders to ensure their rights are protected.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Initiated: Halper Sadeh LLC is investigating RAPT Therapeutics, Inc. (NASDAQ: RAPT) regarding its sale to GSK plc for $58.00 per share, potentially violating fiduciary duties to shareholders and impacting shareholder rights.
- Shareholder Rights Protection: The transaction between Penumbra, Inc. (NYSE: PEN) and Boston Scientific Corporation involves $374.00 in cash or 3.8721 shares of Boston Scientific common stock per share, with Halper Sadeh LLC potentially seeking increased consideration and additional disclosures for shareholders.
- Cash and Stock Transaction: Calavo Growers, Inc. (NASDAQ: CVGW) is selling to Mission Produce, Inc. for $14.85 in cash and 0.9790 shares of Mission stock per share, prompting Halper Sadeh LLC to assess the potential impact of this transaction on shareholders.
- Management Transaction Review: FONAR Corporation (NASDAQ: FONR) is involved in a transaction with its CEO and certain executives for $19.00 per share for Class B common stock and $6.34 per share for Class C common stock, with Halper Sadeh LLC possibly advocating for enhanced shareholder rights.
See More
Investigation Alerts for Multiple Company Mergers
- RAPT Acquisition Investigation: RAPT Therapeutics is set to be acquired by GlaxoSmithKline for $58 per share, totaling an estimated equity value of $2.2 billion, with investigations focusing on whether the board failed to conduct a fair process, potentially impacting shareholder rights.
- Calavo Merger Details: Calavo Growers will be acquired by Mission Produce, with shareholders receiving $27 per share, including $14.85 in cash and 0.9790 shares of Mission, valuing the transaction at approximately $430 million, while investigations examine if the board breached fiduciary duties to shareholders.
- Penumbra Acquisition Status: Penumbra will be acquired by Boston Scientific in a deal valuing the company at $374 per share, reflecting an enterprise value of about $14.5 billion, with investigations looking into whether the board ensured a fair process, potentially affecting shareholder interests.
- FONAR Merger Investigation: FONAR Corporation is to be acquired by FONAR, LLC for $19 per share in an all-cash transaction, with investigations questioning whether the board failed to conduct a fair process, which could impact shareholder rights.
See More
Halper Sadeh LLC Investigates Multiple Companies for Potential Violations
- Investigation Focus: Halper Sadeh LLC is investigating Janus Henderson Group plc, Amicus Therapeutics, Inc., and RAPT Therapeutics, Inc. for potential violations of federal securities laws related to their sales to Trian Fund Management, BioMarin Pharmaceutical, and GSK plc.
- Transaction Details: The cash sale price for Janus Henderson is $49.00 per share, Amicus is $14.50 per share, and RAPT is $58.00 per share, which may not adequately reflect the companies' true values, potentially harming shareholder interests.
- Shareholder Rights Protection: Halper Sadeh LLC may seek to secure increased consideration for shareholders, additional disclosures, and other relief measures to ensure the protection of shareholders' legal rights.
- Legal Service Commitment: The firm operates on a contingency fee basis, meaning shareholders are not responsible for out-of-pocket legal fees, and they encourage affected shareholders to consult for free regarding their legal rights and options.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating Nathan’s Famous, Inc. (NASDAQ: NATH) for potential violations related to its sale to Smithfield Foods, Inc. for $102.00 per share in cash, aiming to protect shareholder rights and seek increased compensation.
- Transaction Details: Penumbra, Inc. (NYSE: PEN) is being sold for $374.00 in cash or 3.8721 shares of Boston Scientific common stock, with Halper Sadeh LLC potentially advocating for more information and compensation to ensure transaction transparency for shareholders.
- Legal Rights: RAPT Therapeutics, Inc. (NASDAQ: RAPT) is selling to GSK plc for $58.00 per share, and Halper Sadeh LLC encourages shareholders to reach out to understand their legal rights and options, ensuring their interests are safeguarded in the transaction.
- Shareholder Support: Lisata Therapeutics, Inc. (NASDAQ: LSTA) is being sold for $4.00 per share in cash plus two non-tradeable rights, with Halper Sadeh LLC offering contingent fee legal services to help shareholders secure their rightful interests in the potential transaction.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde & Associates is investigating the acquisition of Penumbra, Inc. by Boston Scientific Corporation, where shareholders are expected to receive either $374 in cash or 3.8721 shares of Boston Scientific, highlighting a commitment to shareholder rights.
- RAPT Transaction Details: In the sale of RAPT Therapeutics, Inc. to GSK plc, shareholders are anticipated to receive $58 in cash per share, reflecting positive market expectations regarding the transaction's value.
- Nathan's Famous Acquisition: Nathan’s Famous, Inc. is set to receive $102 in cash per share from Smithfield Foods, indicating a direct financial benefit to shareholders from this acquisition.
- Lisata Transaction Terms: Lisata Therapeutics, Inc. shareholders will receive $4 in cash per share along with potential contingent value rights in the sale to Smithfield Foods, suggesting future revenue opportunities for investors.
See More
